ssDNA nanotubes for selective targeting of glioblastoma and delivery of doxorubicin for enhanced survival-Reference-Cited by-同舟云学术

ssDNA nanotubes for selective targeting of glioblastoma and delivery of doxorubicin for enhanced survival

Published:2021-12-03 Issue:49 Volume:7 Page:
ISSN:2375-2548
Container-title:Science Advances
language:en
Short-container-title:Sci. Adv.

Author:

Harris Michael A.¹^ORCID,Kuang Huihui²,Schneiderman Zachary²³^ORCID,Shiao Maple L.⁴,Crane Andrew T.⁴^ORCID,Chrostek Matthew R.⁴^ORCID,Tăbăran Alexandru-Flaviu⁵^ORCID,Pengo Thomas⁶^ORCID,Liaw Kevin³⁷^ORCID,Xu Beibei⁴,Lin Lucy²³^ORCID,Chen Clark C.⁴^ORCID,O’Sullivan M. Gerard⁵^ORCID,Kannan Rangaramanujam M.³⁷^ORCID,Low Walter C.⁴,Kokkoli Efrosini²³^ORCID

Affiliation:

1. Department of Chemical Engineering and Materials Science, University of Minnesota, Minneapolis, MN 55455, USA.

2. Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, MD 21218, USA.

3. Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD 21218, USA.

4. Department of Neurosurgery, University of Minnesota Medical School, Minneapolis, MN 55455, USA.

5. Comparative Pathology Shared Resource, Masonic Cancer Center, University of Minnesota, Saint Paul, MN 55108, USA.

6. University of Minnesota Informatics Institute, University of Minnesota, Minneapolis, MN 55455, USA.

7. Center for Nanomedicine, Department of Ophthalmology, Wilmer Eye Institute Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.

Abstract

DNA nanotubes can cross blood-brain tumor barrier and enhance survival with no toxicity when used for the local delivery of DOX.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference60 articles.

1. Progress Toward Long-Term Survivors of Glioblastoma

2. Longer-term (≥ 2 years) survival in patients with glioblastoma in population-based studies pre- and post-2005: a systematic review and meta-analysis

3. The blood–brain barrier and blood–tumour barrier in brain tumours and metastases

4. Is the blood–brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data

5. Dendrimer size effects on the selective brain tumor targeting in orthotopic tumor models upon systemic administration

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lactoferrin/CD133 antibody conjugated nanostructured lipid carriers for dual targeting of blood–brain-barrier and glioblastoma stem cells;Biomedical Materials;2024-08-22

2. Revealing the mechanisms of blood–brain barrier in chronic neurodegenerative disease: an opportunity for therapeutic intervention;Reviews in the Neurosciences;2024-07-08

3. Engineering nanomaterials for glioblastoma nanovaccination;Nature Reviews Materials;2024-05-23

4. Potential of Nanocarrier-Associated Approaches for Better Therapeutic Intervention in the Management of Glioblastoma;ASSAY and Drug Development Technologies;2024-03-01

5. Novel Nanotechnological Therapy Approaches to Glioblastoma;Recent Progress in Pharmaceutical Nanobiotechnology: A Medical Perspective;2023-12-27